---
run_id: halo-evidence-vs-diagnosis-validation-v9-generic-advice-prompted-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: generic_advice_prompted
run_number: 1
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 105
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `generic_advice_prompted`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 105, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) and surface-level usage metrics (39% increase) are being driven by incentives (bundle pricing), managerial vanity/reporting (ops managers rerunning samples), and sales narratives (roadmap pitches).

The core risk is that DraftPath provides **perceived value** to the buyer (the person signing the check) but lacks **functional utility** for the user (the adjuster). In B2B workflow software, this gap is a leading indicator of catastrophic churn.

Here is why the other options are insufficient:
*   **Scale Broadly:** This is reckless. You have evidence of "novelty spikes" (heavy use for two days, then abandonment) and a failure in the health-liability segment. Scaling a leaky bucket only accelerates churn.
*   **Usage Quality Sprint:** This measures *how often* people click, not *why* they stop. High return rates could simply be managers forcing adoption. It doesn't solve the "explainability" crisis in regulated segments.
*   **Commercial Cleanroom:** This tests price elasticity and sales messaging, but it doesn't tell you if the product actually works. If the product is fundamentally flawed for the adjuster, a "cleanroom" only proves that you can't sell a bad product without a discount.
*   **Narrow to Health-Liability:** This is a premature pivot based on one failure point. You don't yet know if the issue is the product’s logic or simply a lack of "audit trail" features for regulators.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (acceptance vs. override). This will tell you if DraftPath is a productivity tool or a "theatre" tool.

### The Trade-off
By choosing the Claim File Review, you are **displacing the Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to know exactly how much "pricing power" DraftPath has in a vacuum. You will enter the next fiscal year without knowing if you can maintain expansion margins without bundle discounts. You are choosing *product-market fit* over *price-market fit*.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a snapshot of a small sample size rather than the aggregate data of a "Sprint." If the board is purely focused on the 12-day budget window, they may view a qualitative review as "too academic" compared to the hard financial data of a Cleanroom or the scale-up potential of broad deployment. It does not provide an immediate "revenue" answer, only a "risk" answer.

### Evidence That Would Change My Mind
I would switch my recommendation to **Narrow the company plan around regulated health-liability workflows** if the Claim File Review reveals that the "impossible to explain" feedback is not a feature gap, but a fundamental limitation of your AI/logic engine.

If the audit shows that adjusters *want* to use the tool but are legally prohibited from doing so because of the "black box" nature of the suggestions, you no longer have a general workflow problem—you have a regulatory compliance problem. In that case, the only path to survival is to rebuild the product specifically for the constraints of regulated health-liability.
